Evidence for a stable interaction of gp41 with Pr55(Gag) in immature human immunodeficiency virus type 1 particles.
about
The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particlesIdentification of the cellular prohibitin 1/prohibitin 2 heterodimer as an interaction partner of the C-terminal cytoplasmic domain of the HIV-1 glycoproteinEnvelope glycoprotein cytoplasmic domains from diverse lentiviruses interact with the prenylated Rab acceptor.Low pH is required for avian sarcoma and leukosis virus Env-dependent viral penetration into the cytosol and not for viral uncoatingVirus entry, assembly, budding, and membrane raftsConformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1Structural and functional comparisons of retroviral envelope protein C-terminal domains: still much to learnUnderstanding the process of envelope glycoprotein incorporation into virions in simian and feline immunodeficiency virusesNucleocapsid promotes localization of HIV-1 gag to uropods that participate in virological synapses between T cellsCell-to-cell contact facilitates HIV transmission from lymphocytes to astrocytes via CXCR4.Cytopathic Mechanisms of HIV-1Characterization of Hepatitis C Virus Core Protein Multimerization and Membrane Envelopment: Revelation of a Cascade of Core-Membrane InteractionsTopology of the C-terminal tail of HIV-1 gp41: differential exposure of the Kennedy epitope on cell and viral membranesT cell virological synapses and HIV-1 pathogenesis.C-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic.Electron cryotomography of immature HIV-1 virions reveals the structure of the CA and SP1 Gag shells.In vitro protease cleavage and computer simulations reveal the HIV-1 capsid maturation pathway.Evidence that Gag facilitates HIV-1 envelope association both in GPI-enriched plasma membrane and detergent resistant membranes and facilitates envelope incorporation onto virions in primary CD4+ T cells.Chimeric human immunodeficiency virus type 1 virions that contain the simian immunodeficiency virus nef gene are cyclosporin A resistant.The late stage of human immunodeficiency virus type 1 assembly is an energy-dependent process.Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag.Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail.Amino acid residues in the cytoplasmic domain of the Mason-Pfizer monkey virus glycoprotein critical for its incorporation into virions.Maturation-induced cloaking of neutralization epitopes on HIV-1 particles.Palmitoylation of the murine leukemia virus envelope protein is critical for lipid raft association and surface expression.A mutation in the human immunodeficiency virus type 1 Gag protein destabilizes the interaction of the envelope protein subunits gp120 and gp41.Intracellular trafficking of Gag and Env proteins and their interactions modulate pseudotyping of retroviruses.Independent segregation of human immunodeficiency virus type 1 Gag protein complexes and lipid rafts.Identification of a small-molecule inhibitor of HIV-1 assembly that targets the phosphatidylinositol (4,5)-bisphosphate binding site of the HIV-1 matrix protein.Increased functional stability and homogeneity of viral envelope spikes through directed evolution.Gag regulates association of human immunodeficiency virus type 1 envelope with detergent-resistant membranes.Detailed topology mapping reveals substantial exposure of the "cytoplasmic" C-terminal tail (CTT) sequences in HIV-1 Env proteins at the cell surface.Rapid localization of Gag/GagPol complexes to detergent-resistant membrane during the assembly of human immunodeficiency virus type 1.Macrophages and Cell-Cell Spread of HIV-1.Targeting the HIV entry, assembly and release pathways for anti-HIV gene therapy.HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation.HIV-1 matrix protein binding to RNA.Highly conserved structural properties of the C-terminal tail of HIV-1 gp41 protein despite substantial sequence variation among diverse clades: implications for functions in viral replication.Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion.Bifunctional anti-human immunodeficiency virus type 1 small molecules with two novel mechanisms of action.
P2860
Q21245046-1023CEDD-F468-40AE-B3A4-82B3BF0F603EQ24316304-5A1E3822-3A86-4871-9248-6CC8C568F3DDQ24540298-5F2D244E-0ED7-43C6-80AD-CC495C5A6045Q24562016-4AF2D901-3F93-4DC7-8467-7B99CCA0BCCDQ24673161-AFD4BBB9-8A49-4895-B137-A25931E99D3CQ26782237-C22B87D8-993C-4E58-9EE3-12C7C0879E8DQ26862369-D3C08316-84FF-4ABE-B870-5D1069E1BB0FQ27021655-2D064ABE-30F9-446C-8F28-D487AD4E1373Q27312753-F5DA4AFA-0F7C-4CD8-8885-A3964B01D2CCQ27313520-7AA38D0C-73FB-4C2C-A00E-902003F65FBAQ27485043-71299DA6-03BE-470C-BF37-B786BCA748DFQ27489695-CD4E4143-3179-412B-9F9D-197369BC033DQ28476449-5687B432-B592-4EC6-A2E7-2A0370AD5600Q30415010-42D2745D-1B3E-41F9-AD60-623CD1DD1583Q30422545-A96AC735-8297-4E2C-97D4-CAB34DB93D6AQ30479297-5612566B-F3A1-4DB7-829D-FE8070FF701BQ30832180-7E7E4528-2894-4351-ABBD-2CCFDD564468Q33645234-8ED884E9-1F40-4877-9254-96FDB8B7F2B6Q33834565-9254C2AE-F43C-4FEA-ABA2-C0D273C46025Q33841842-B2516371-99B4-4D67-A47F-CA3EC2A7F4BBQ33841920-56B8BF61-78B9-494A-A094-8721B7FD43B5Q33984243-C5AD7368-3F47-4253-A5A5-B50757FF749BQ33987373-97F8899E-65B8-4C2E-874B-D5F745EF0AFCQ34023008-B1D153D3-0C55-495E-82D7-8AE54DCED6EEQ34359777-B8A39E36-6C94-4C6C-89A2-1D50E68EAE2FQ34434813-11DBF235-9A84-4F9D-8110-5AB97E954C2AQ34439347-A94EC7F2-EC8A-4940-9CE5-83E9EA18C5EFQ34466295-6F2DDA7F-1647-4374-B191-45B23366B3E7Q34567234-B9A887FA-4794-482D-8CF6-14090FF751D0Q34611144-1632F1D6-F27B-4071-A7C2-1F393AB1C8ECQ34648092-1BECE068-FB12-4556-9E78-5746B69F9E29Q34750051-DA6C0F6F-14F9-4ECE-9BAD-7759E01BC6DBQ34781698-F2B25D5F-4FF6-4F3C-9F21-70F5C86202CEQ34931267-A66B21E2-0839-4C51-BF7B-DDCEE82F2DE8Q35024116-385D8FF4-254C-480D-8753-3F27F96C10F5Q35113720-3E55CF7C-CE63-4640-8732-A3E1B49AD076Q35114688-3EF511B8-E5E8-4F80-970D-1ED27AC0499AQ35144796-2C696B90-4B67-4385-9A44-79377CF951A7Q35215251-7988C6E1-9104-4FAA-8403-4279FA8C3CADQ35548195-1EFED2D1-41F9-4E33-B9AA-371E9896D0F4
P2860
Evidence for a stable interaction of gp41 with Pr55(Gag) in immature human immunodeficiency virus type 1 particles.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Evidence for a stable interaction of gp41 with Pr55
@nl
Evidence for a stable interact ...... ciency virus type 1 particles.
@en
type
label
Evidence for a stable interaction of gp41 with Pr55
@nl
Evidence for a stable interact ...... ciency virus type 1 particles.
@en
prefLabel
Evidence for a stable interaction of gp41 with Pr55
@nl
Evidence for a stable interact ...... ciency virus type 1 particles.
@en
P2093
P2860
P1433
P1476
Evidence for a stable interact ...... ciency virus type 1 particles.
@en
P2093
P2860
P304
P356
10.1128/JVI.74.20.9381-9387.2000
P407
P577
2000-10-01T00:00:00Z